EL7.AI
Mergers & AcquisitionsMedium•16 November 2026•
3 min read

EL7 Data Confirms Johnson & Johnson Closed at $285.75 on November 13

Key Facts

1Johnson & Johnson shares closed at $285.75 on November 13, 2026.
2Ollin announced $330 million in Series B financing on June 24, 2026.
3Ollin said nearly 90% of patients with diabetic macular edema who received OLN324 at a 4 mg dose showed no signs of disease at Week 12, compared with 57% with faricimab.
4The JADE study included 164 U.S. patients, with follow-up lasting 20 weeks.

Johnson & Johnson shares closed at $285.75 in the November 13, 2026 session, according to EL7 data. The price comes amid reports of talks to acquire Ollin Biosciences, but the existence of the talks and the deal value could not be verified through a reliable open source. The acquisition therefore cannot be presented as a confirmed agreement, nor can the share close be attributed to the report. The closing price remains a dated reference for that session, not evidence of a market response to news whose timing relative to the session has not been established.

Ollin’s announcements provide background on the company’s work in ophthalmology. At its launch, it said it was focused on developing treatments in the field and pointed to its OLN102 program. It said the program targets thyroid eye disease and Graves’ disease using a bispecific antibody targeting TSHR and IGF-1R. The company described it as first-in-class, with the potential for best-in-class safety and efficacy, according to the wording of its announcement. This places its stated activity in the field of eye treatments, without confirming any link between these assets and the reported deal.

On June 24, 2026, Ollin announced a $330 million Series B financing to support the global Phase 3 development of its OLN324 program. It said the financing was co-led by TCGX and ARCH Venture Partners. The announcement linked the financing to development of the treatment in studies of diabetic macular edema and wet age-related macular degeneration, the two areas targeted by its stated development plan. The financing gives an indication of the resources the company said it had allocated to the program, but does not establish Ollin’s value or any potential acquisition price.

On January 8, 2026, Ollin announced topline results from a study comparing OLN324 with faricimab in patients with diabetic macular edema. It said nearly 90% of patients who received a 4 mg dose of OLN324 showed no signs of disease at Week 12, compared with 57% of patients who received faricimab. The company presented these figures as topline results and specified the treatment dose and measurement time for the comparison. These results alone do not establish regulatory approval or a final outcome, and they do not address acquisition talks.

On March 30, 2026, the company announced completion of 20 weeks of follow-up in the JADE study, which included 164 U.S. patients with diabetic macular edema or wet age-related macular degeneration. The follow-up announcement came after the topline results it published in January, adding a later milestone in the program’s evaluation. Ollin specified the number of participants and the duration when it announced the study’s final results, but the information available here does not include additional figures for comparison at Week 20. These results remain background on OLN324’s development, not confirmation of the reported deal’s terms.

Under the plan Ollin announced in June, the company was targeting the start of global Phase 3 trials for OLN324 in the second half of 2026. It linked that timeline to development of the treatment for diabetic macular edema and wet age-related macular degeneration. The trial start date is the next stated step in the program’s development, while the information provided does not show whether that milestone was reached. The information also contains no documented disclosure from Johnson & Johnson or Ollin of an agreement or acquisition offer, leaving the alleged deal unconfirmed.

Open on chart